Immunotherapy extends survival in patients with advanced bladder cancer
An immunotherapy drug called 'avelumab' has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
.png)
No hay comentarios:
Publicar un comentario